A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor

BACKGROUND: Preclinical studies suggest that imatinib resistance in gastrointestinal stromal tumor (GIST) can be mediated by MAP-kinase activation via fibroblast growth factor (FGF) signaling. In FGF stimulated GIST cell lines, BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib, was cy...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Invest New Drugs
Huvudupphovsmän: Kelly, Ciara M., Shoushtari, Alexander N., Qin, Li-Xuan, D’Angelo, Sandra P., Dickson, Mark A., Gounder, Mrinal M., Keohan, Mary Louise, Mcfadyen, Chloe, Sjoberg, Ana, Singer, Samuel, DeMatteo, Ronald P., Hwang, Sinchun, Heinemann, M.H., Francis, Jasmine H., Antonescu, Cristina R., Chi, Ping, Tap, William D.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2018
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6714550/
https://ncbi.nlm.nih.gov/pubmed/30101387
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-018-0648-z
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk